3Brache V, Payan LJ, Faundes A. Current status of con- traceptive vaginal rings [J]. Contraception, 2013, 87( 3 ) : 264-272.
4Wieder DR, Pattimakiel L. Examining the efficacy, safe- ty, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing) [J]. Int J Womens Health, 2010, 2:401-409. doi: 10. 2147/IJWH. $6162.
5Roumen FJ, Apter D, Mulders TM, et al. Efficacy, tol- erability and acceptability of a novel contraceptive vaginal ring releasing etonogestel and ethinyl oestradiol [J]. Hum Reprod, 2001, 16(3) :469-475.
6Kerns J, Darney P. Vaginal ring contraception[J]. Con- traception, 2011, 83 (2) : 107-115.
7Mohamed AM, E1-Sherbiny WS, Mostafa WA. Com- bined contraceptive ring versus combined oral contracep- tive (30-p~g ethinylestradiol and 3-mg drospirenone ) [J].Int J Gynaecol Obstet, 2011, 114(2) :145-148.
8Roumen FJ, Mishell DR Jr. The contraceptive vaginal ring, NuvaRing (R), a decade after its introduction[J]. Eur J Contracept Reprod Health Care, 2012, 17(6) : 415- 427.
9De Seta F, Restaino S, De Santo D, et al. Effects of hormonal contraception on vaginal flora [J].Contracep- tion, 2012, 86(5) :526-529.
10Simhan HN, Anderson BL, Krohn MA, et al. Host im- mune consequences of asymptomatic trichomonas vagina- lis infection in pregnancy [J]. Am J Obstet Gynecol, 2007, 196(1) :59. el-5.
